Pacira BioSciences, Inc. (PCRX)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Pacira BioSciences, Inc. keeps $2 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Pacira BioSciences beat expectations on adjusted EPS while revenue came in line with consensus, as its second fiscal quarter of 2026 results reported August 4, 2026 showed revenue up 6.2% year over year to roughly $192.4 million. On the bottom line, adjusted EPS of $0.73 topped the $0.65 estimate (+13%), while revenue of $192.4 million was in line with the $191.1 million estimate (+0.7%). Profitability remained high on a gross basis, with gross profit of about $148.2 million translating to a gross margin near 77%, and operating income of roughly $4.3 million for an operating margin around 2.2%. Net income was about $4.7 million, a swing from net income of -$4.8 million a year ago. The quarter also generated operating cash flow of about $57.5 million. For the next period, consensus calls for EPS of $0.76 on revenue of $181.8 million.
Next report — what to expect
Pacira BioSciences, Inc. (PCRX) reports on November 5, 2026. Wall Street is looking for consensus EPS of $0.731 on consensus revenue of $183.0 million. For trailing context, revenue grew 6.2% year over year last quarter. Pacira has beaten EPS in 6 of its 8 most recent quarters.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. develops and sells non-opioid pain-management and regenerative-health products in the healthcare sector. Listed on NASDAQ as PCRX, the company markets prescription therapies and a medical device in the United States, generating $726.4 million of revenue in FY2025.
Today's Snapshot
The day ended with PCRX slightly higher at 36.42, while its sector was weaker. Volume was about two-fifths of its usual level. Analysts raised Pacira BioSciences’ fair-value estimate to $33.57 after drugmaker Viatris agreed to buy it for $36.50 a share.
Trading Volume
Below 10d avg (1.5M)
574.3K
vs S&P 500 Today
Outperforming Market
+0.74%
Updated: October 23, 2026 at 20:21 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$25.45 - $35.35Buy
- RSI (14)83.79Sell
- Stochastic %K (14, 3, 3)97.47Sell
- MACD Level (12, 26)2.95Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.